follow-up data from the CMF Milan experience suggest that even at that time no plateau has been reached. 7 Several studies and retrospective analyses suggest a sigDespite adjuvant chemotherapy the prognosis of patients with breast cancer and a high number of nificant dose-response relationship in metastatic and primary breast cancer. [8] [9] [10] [11] Attempts to further improve these involved axillary lymph nodes is very poor. The aim of the present study was to evaluate the efficacy of highresults by increasing the dose of chemotherapy have met only limited success, mainly due to profound myelodose chemotherapy with autologous bone marrow support in patients with seven or more involved axillary suppression. Autologous bone marrow support (ABMS) offers an opportunity to overcome this problem, but lymph nodes. Nineteen patients underwent four courses of standard adjuvant chemotherapy, followed by highwhether this will lead to better results remains to be determined. dose busulphan/cyclophosphamide chemotherapy with autologous bone marrow support. The median age was High-dose cyclophosphamide has been shown to induce responses in a variety of relapsed or refractory malig-41.4 years and the median number of involved lymph nodes 11. Mucositis WHO grade у3 was observed in nancies and has been part of double alkylator therapy with autologous bone marrow support in advanced breast can-15 patients and 18 patients suffered febrile neutropenia. Transplant-related mortality was encountered in two cer. [12] [13] [14] Alkylating agents have shown a steep doseresponse relationship in vitro and, when combined, act patients, due to hepatic veno-occlusive disease and sepsis complicated by multi-organ failure, respectively.
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synergistically to produce response rates higher than those produced by single agents alone.
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After a median follow-up period of 1490 days (range 582-2024 days) from diagnosis, nine patients have The preparative regimen busulphan and cyclophosphamide (BuCy) was introduced by Santos and colleagues 17 for relapsed and the overall event-free survival (EFS) is 42% (95% CI 19-65%). The median EFS is 487 days.
the treatment of acute non-lymphoblastic leukaemia. This regimen was altered to decrease the toxicity of cyclophosHigh-dose treatment with BuCy2 in high-risk breast cancer patients is a toxic regimen and does not seem to phamide (BuCy2) by Tutschka and coworkers 18 without apparent loss of efficacy. Experience with BuCy2 showed improve disease-free survival. Keywords: adjuvant; bone marrow transplantation; a relatively low treatment-related morbidity, making this bi-alkylator preparative regimen potentially attractive for breast neoplasms drug therapy; busulphan; cyclophosphamide the treatment of solid tumors. 19 In 1991, we started a phase II study to address the question of whether adjuvant chemotherapy followed by highdose consolidation with busulphan and cyclophosphamide Adjuvant chemotherapy has demonstrated a modest, but supported by bone marrow transplantation will improve the consistent improvement in long-term disease-free and overprognosis of patients with primary breast cancer and seven all survival in primary breast cancer patients. 1 The progor more positive axillary lymph nodes. nosis of patients with primary breast cancer is inversely related to the number of involved axillary lymph nodes at surgery. Analysis of treatment outcomes in patients with Materials and methods four to nine positive lymph nodes indicates that 50-60% will relapse by 5 years and 60-70% will relapse by 10 Patients years.
2-4 The outcome of patients with 10 or more positive lymph nodes is even worse: at 5 years 55-87% and at 10 Patients were eligible if they had histologically proven years 70-90% have relapsed, respectively. (Table 1 ). breast. Bone marrow was harvested 4 weeks after the third Three patients had 7-9, 13 patients 10-20 and three patients cycle if routine physical and laboratory examination у21 involved lymph nodes, respectively. The estrogenappeared normal. Bone marrow was harvested under genreceptor was positive in nine patients. eral anesthesia by multiple aspirations from both posterior iliac crests and at least 0.5 ϫ 10 8 nucleated cells/kg body weight were collected. A buffy coat concentrate was cryoToxicity of high-dose chemotherapy preserved using 10% dimethyl sulfoxide, frozen at a controlled rate and stored in liquid nitrogen. After the harDuring the conditioning regimen all patients suffered from vesting procedure, a fourth chemotherapy cycle was nausea and vomiting which were alleviated by selective 5-administered. Between 4 and 6 weeks after this fourth cycle HT 3 antagonists. Mucositis WHO grade у3 was observed patients were admitted for the high-dose consolidation in 15 patients, making total parenteral nutrition necessary in chemotherapy. All patients had a double-lumen central 12 patients. After the high-dose chemotherapy, the median venous catheter placed and were cared for in private rooms duration from bone marrow reinfusion to ANC with positive-pressure, high efficiency particle filtration air Ͼ0.5 ϫ 10 9 /l was 12 days (range 11-26). The median dursystems. Prophylactic measures consisted of a low bacterial ation to unsupported platelets у20 ϫ 10 9 /l was 32 days and low fungal content diet, oral fungostatics and oral quin-(range 12-131) days. Eighteen patients suffered from one olones. The high-dose chemotherapy program consisted of or more episodes of febrile neutropenia. Transplant-related busulphan 4 mg/kg p.o. in divided doses daily from days mortality was encountered in two patients both without evi-Ϫ7 to Ϫ4 (total dose 16 mg/kg) and cyclophosphamide 60 dence of relapse (Table 1 , patients 6 and 19). One patient mg/kg once daily i.v. on days Ϫ3 and Ϫ2 (total dose 120 died at day 58 post-transplant due to a complicated acalmg/kg), followed by bone marrow reinfusion on day 0. culic cholecystitis with septicemia and ultimately multiple Throughout the treatment course hemoglobin level was organ failure. The second patient developed progressive maintained above 6 mmol/l and the platelet count above hepatic veno-occlusive disease (VOD) 60-days post-trans-10 ϫ 10 9 /l by transfusion of irradiated leukocyte-poor plant, complicated by interstitial pneumonitis, and ultidonor red cells and random platelets. During the study permately died 131 days post-transplant. VOD was also iod the hematopoietic growth factors GM-CSF and later Gobserved in another patient 37 days post-transplant, who CSF became available, and were administered, according made an uneventful recovery. to local protocols at a dose of 5 g/kg body weight, from day 1 until leukocyte recovery у3 ϫ 10 9 /l. Cultures were performed for bacterial and fungal infections if a patient's Survival temperature was greater than 38.5°C. Febrile neutropenic patients were treated empirically by a standardized antiAfter a median follow-up of 1490 days (range 582-2024 biotic protocol. Prescription of tamoxifen after hematologic days) from diagnosis, the overall EFS is 42% (95% CI 19-recovery was left to the discretion of the physician. 65%) (Figure 1 ). The median EFS is 487 days (192-1838+) and the median OS was reached after 894 days. There were Follow-up two treatment-related deaths. Nine out of the 17 remaining patients developed relapsed disease, with a median time to After transplantation patients were followed with monthly relapse of 395 days (range 200-559). Six patients had syscontrols in the first year and three monthly controls later, temic relapses with localizations in the liver, bone, lung, using history, routine physical examination, liver enzyme central nervous system and/or bone marrow (Table 1) . One testing and yearly mammography. patient relapsed only in the CNS. One patient relapsed locoregionally, and was treated with radiotherapy, and she Statistics developed liver and bone metastasis 7 months later. Another patient relapsed in the mastectomy scar and was Event-free survival (EFS) was defined as the time from surgery until relapse or death. Overall survival (OS) was calcutreated with local excision and radiotherapy. Mast = mastectomy; Lump = lumpectomy; lnn = lymph nodes; CNS = central nervous system; C = cyclophosphamide; A = doxorubicin; F = fluorouracil; E = epi-doxorubicin; M = methotrexate; EFS = event-free survival; OS = overall survival in days. a Therapy-related mortality. 
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Figure 1 Actuarial probability of overall survival (-͉ -) and event-free survival (-̅ -) for patients with primary breast cancer with seven or more involved auxillary lymph nodes, treated with consolidation high-dose chemotherapy and autologous bone marrow support.
Discussion autologous bone marrow support in patients with primary breast cancer and at least seven involved axillary lymph nodes. With a relatively short follow-up we encountered We report our results of conventional adjuvant chemotherapy followed by high-dose BuCy2 chemotherapy with a disappointing event-free survival (42%), which may be comparable with the results of conventional adjuvant transfusion of peripheral blood stem cells (PBSC). There appears to be some clinical benefit from PBSC, including a chemotherapy.
At Duke University, in a phase II study Peters et al 22 reduced duration of aplasia and hospitalization. 35 However, much of the therapy-related mortality observed is due to used high-dose cyclophosphamide, cisplatinum and carmustine with autologous stem cell support as consolidation the organ toxicity due to the conditioning regimen and is independent of the source of hematopoietic support. One after four cycles of standard-dose adjuvant chemotherapy treatment of primary breast cancer involving 10 or more advantage of PBSC over ABMS could be a reduced risk of tumor cell contamination. However, Brugger et al 36 axillary nodes. At a median follow-up of 3.3 years the EFS was 72% (95% CI 55-82%). At a recent update with a showed in a high proportion of patients concomitant tumor cell recruitment upon mobilization of PBSCs. Therefore, it median follow-up of 5 years the EFS was 71% (95% CI 53-84%). 23 De Graaf et al 24 reported their experience of is unlikely that our results would have been improved by the use of PBSCs. Randomized prospective trials are high-dose consolidation with ABMS in patients with five or more positive axillary lymph nodes. With a median folneeded to prove the real value of PBSC with regard to survival and cure. low-up of 36 months the DFS was 84%. Tomás and coworkers 25 recently published their high-dose experience in Due to the small sample size (19 patients) and relatively high mortality rate (11%) it is not possible to draw firm 40 patients with 10 or more positive nodes and observed an EFS of 72% (95% CI 66-81%) at 3 years. Several other conclusions. However, our data do not seem to support the use of high-dose chemotherapy followed by stem cell transinvestigators have recently reported their experiences with high-dose consolidation in this high-risk breast cancer plantation as adjuvant therapy in high risk primary breast cancer. patient group. With a relatively short median follow-up (7-16 months) the disease-free survival shows a broad range Presently, two large cooperative group (ECOG, CALGB) randomized trials evaluating the role of high-dose chemobetween 67% and 90%.
26-30 Garcia-Conde et al 31 reported the Spanish results of a phase II study of high-dose consolitherapy in patients with 10 or more positive nodes are ongoing. In January 1994, a randomized study was started dation in patients with 10 or more involved lymph nodes and observed a 2-year DFS of 80% and a 4-year DFS of in The Netherlands to investigate the value of high-dose chemotherapy in patients with four or more involved axil-70%, respectively.
How can we explain this discrepancy in results? It should lary lymph nodes. The results of these randomized studies should determine if high-dose chemotherapy has a definibe noted that in our trial the patients were not screened intensively for metastatic disease at diagnosis, or at the time tive place. of bone marrow harvest. From a recent report we know when patients with 10 or more positive nodes are screened more vigorously, with bone marrow biopsies and computed Acknowledgements tomography scans, up to 27% are found to have detectable disease, which would have been missed with our preWe thank the nursing staff of the Hematology-Oncology ward for their care and part in the treatment of these patients. Our colstudy screening. conventional adjuvant chemotherapy in this high-risk patient group. Klumpp et al 33 investigated a standard BuCy preparative regimen in relatively heavily pretreated patients References (median of two prior chemotherapy regimens, range 1-3) with advanced chemosensitive breast cancer (CR 13%).
